|Day Low/High||21.46 / 22.73|
|52 Wk Low/High||5.98 / 30.90|
It makes logical sense to take your foot off the gas here.
It is logical that stocks consolidate a little as we head into earnings season.
As the pundits decide who won, I'm looking at these biotech names with a focus on Myovant Sciences.
Shares of Heron Therapeutics and Myovant Sciences have taken hits but both companies still show promise.
You need to be selective and manage positions carefully.
As this healthy bounce boosts the market, I'm seeing opportunities in these special purpose acquisition companies.
Here are several names I'm looking to build on further weakness.
Small-caps are also benefitting from the move, but momentum-chasing has slowed.
Biotechnology is always high risk but the right plays move unlike anything else.
It continues to be a market for speculative trading.
I'm doing some dip buying amid weakness in large-cap tech stocks.
The good news right now is that selling is not highly correlated.
The market trend is up and that's all that matters in the short term.
It continues to be a very good market for aggressive traders that focus on stock-picking and sectors.
A weak close will be a key sign that a change in character might be coming.
If the market can't sell off on this news then what reason does it have to dip?
Simply Good Foods and Myovant Sciences looked poised to see their shares rise over the longer term.
The Medical Technology Stock Letter's top pick rose 357% in 2019.
More sedate action on the eve of the holiday is the order of the day so far.
Experts offer their top stock ideas in oncology detection and treatment.
These favorite names in the volatile sector offer the potential for high rewards.